FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 406 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS) February 7, 2019 News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... July 11, 2020 FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma August 24, 2021 HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... August 7, 2023 Load more HOT NEWS How to Find Reliable and Affordable Transportation During Cancer Dame Deborah James: why do deeply personal stories resonate with us... New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma How to Maintain Your Sexual Health During and After Lung Cancer
